EGFR and non-small cell lung carcinoma: NSCLC patients with exon 18, 19, 20, and 21 mutations, alterations in EGFR copy number, could potentially disrupt receptor downregulation mechanisms, leading to continuous receptor activation and aberrant signaling pathway activation, which may impact cell cycle regulation and mitotic control.